We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

1 hedge funds and large institutions have $43K invested in ProShares UltraShort NASDAQ Biotechnology in 2013 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less funds holding

Funds holding: 2 → 1 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

85% less capital inflows, than outflows

Capital inflows: $50.1K | Capital outflows: $331K

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$50.1K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$310K
2
UBS
UBS
Switzerland
-$21.2K

BIS Hedge Fund Activity: Q4 2013 in Review

1 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2013, worth a combined $43K — down 87% from $333K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of BIS and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $50.1K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $310K sold.

  • 1 institutional investor held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2013, down from 2 in Q3 2013.
  • Funds reported $43K of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2013, down 87% quarter-over-quarter.
  • 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2013 and 2 closed out, a net change of -1 holder.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2013 was Tower Research Capital (TRC), an estimated $50.1K added.
  • The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2013 was Susquehanna International Group, an estimated $310K sold.

Based on aggregated 13F filings for Q4 2013.